Company: SCLXW
Filing Date: 2025-08-04
Form Type: S-1
Source: 0001193125-25-172703
Chunk: 609

Company: Scilex Holding Co
Filing Date: 2025-08-04
Form: S-1
Chunk 609
---
 Warrant is $1.20 per share. The Registrant received $0.3 million from the exercise of the Fee Warrant, when it was exercised in full in October 2024. |

| • |     | Upon effectiveness of this registration statement, the Registrant is obligated to issue 150,000 shares of Common Stock to Tumim Stone Capital, LLC, a Delaware limited liability company (“Tumim”), in consideration for Tumim’s irrevocable commitment to purchase shares of Common Stock pursuant to the common stock purchase agreement the Registrant entered into with Tumim on July 22, 2025. |

The Registrant issued the foregoing securities in transactions not involving an underwriter and not requiring registration under Section 5 of the Securities Act in reliance on the exemption afforded by Section 4(a)(2) thereof.

II-3

#### Stock (the “Existing Tranche B Warrants”). Pursuant to the Warrant Exchange Agreements, the Registrant and the Exchanging Warrant Holders, in reliance on Section 3(a)(9) of the Securities Act, effected a voluntary securities exchange whereby the Exchanging Warrant Holders exchanged the Existing Tranche B Warrants, which were exercisable for an aggregate of 107,142 shares of Common Stock at an exercise price of $36.40 per share, originally issued pursuant to that certain Securities Purchase Agreement, dated October 7, 2024, by and among us and the investors named therein, for warrants to purchase an aggregate of 500,000 shares of Common Stock at an exercise price of $40.00 per share.The Registrant issued the foregoing securities in transactions not involving an underwriter and not requiring registration under Section 5 of the Securities Act in reliance on the exemption afforded by Section 3(a)(9) thereof.Item 16. Exhibits and Financial Statements Schedules.a)ExhibitsThe following exhibits are filed as part of this registration statement:ExhibitNumberDescription2.1#Agreement and Plan of Merger, dated as of March 18, 2019, by and among Scilex Holding Company, Sigma Merger Sub, Inc., Semnur Pharmaceuticals, Inc., Fortis Advisors LLC, solely as the representative of the Equityholders and, solely with respect to Section 1.8(a), Section 3.11 and Article X, Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 of Amendment No. 1 of